Harold I. Feldman, MD, MS; Michael P. Madaio, MD
To the Editors: Although the report by Falk and associates (1) provides new data regarding the prognosis and therapy of membranous glomerulopathy, several aspects of this study limit its general applicability to the treatment of patients with progressive forms of this disease.
A convincingly negative clinical trial should have a power of 80% or greater. Table 1 is based on the comparison of two survival distributions (2) using data provided in the paper. For this purpose the median renal survival in the study's steroid only treated group was taken as either 30 or 36 months from randomization. This assumption is
Feldman HI, Madaio MP. Cyclophosphamide in Progressive Membranous Glomerulopathy: Pro and Con. Ann Intern Med. ;117:696–697. doi: 10.7326/0003-4819-117-8-696
Download citation file:
Published: Ann Intern Med. 1992;117(8):696-697.
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use